Stockscreener 앱 받기
3.81
2.31%
-0.09
시간 외 거래:
3.78
-0.03
-0.79%
전일 마감가:
$3.90
열려 있는:
$3.89
하루 거래량:
447.36K
Relative Volume:
0.58
시가총액:
$291.33M
수익:
$114.70K
순이익/손실:
$-12.82M
주가수익비율:
-1.4251
EPS:
-2.6735
순현금흐름:
$-45.71M
1주 성능:
+7.32%
1개월 성능:
+8.24%
6개월 성능:
-5.69%
1년 성능:
+110.50%
1일 변동 폭
$3.73
$3.92
1주일 범위
$3.5902
$3.9741
52주 변동 폭
$1.60
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
명칭
Sab Biotherapeutics Inc
전화
305-845-2813
주소
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.81 | 298.21M | 114.70K | -12.82M | -45.71M | -2.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-02 | 개시 | Rodman & Renshaw | Buy |
| 2025-12-19 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 개시 | Leerink Partners | Outperform |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-10-09 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
Citi Initiates SAB Biotherapeutics(SABS.US) With Buy Rating, Announces Target Price $11 - Moomoo
Citigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SABS Q1 2026 Earnings: Wider-than-Expected Loss as Biotech Continues Development; Shares Edge HigherFinancial Health Score - Newser
Jefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SABS Initiated Coverage by Jefferies -- Rating Set to Buy - GuruFocus
Jefferies Initiates SAB Biotherapeutics at Buy With $11 Price Target - Moomoo
Jefferies initiates SAB Biotherapeutics stock with buy on diabetes therapy potential - Investing.com Australia
This QuickLogic Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Sahm
SAB Biotherapeutics Q1 earnings call highlights - MSN
Why Is SAB Biotherapeutics, Inc. (SABSW) Stock Up Today? - Meyka
Number of shareholders of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
Certain Restricted Stock Grants of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026. - marketscreener.com
Certain Warrants of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026. - marketscreener.com
47,609,899 Common Stock of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026. - marketscreener.com
Guggenheim Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Perceptive Advisors (SABS) discloses 8.4% ownership — 6.43M shares - Stock Titan
Caligan Partners, David Johnson hold 10.4% of SAB Biotherapeutics (NASDAQ: SABS) - Stock Titan
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully - Yahoo Finance
Balyasny Asset Mgmt (SABS) discloses ~9.99% ownership, including warrants - Stock Titan
Chardan Capital Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $14 - Moomoo
SAB Biotherapeutics Q1 2026 Earnings Call Transcript - MarketBeat
SAB Biotherapeutics 1Q Research and Development Expenses $13.4M >SABS - Moomoo
SAB Biotherapeutics Q1 Earnings Call Highlights - sharewise.com
H.C. Wainwright raises SAB Biotherapeutics price target on share count By Investing.com - Investing.com Canada
SAB Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
SAB Biotherapeutics (NASDAQ:SABS) Reports Q1 2026 Miss as Clinical Progress and Extended Cash Runway Through 2028 Take Center Stage - ChartMill
Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call - Benzinga
SAB Biotherapeutics raises $95M, expects trial data in 2H 2027 - Investing.com UK
SAB Biotherapeutics raises $95M, expects trial data in 2H 2027 By Investing.com - Investing.com South Africa
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights - The Manila Times
SAB Biotherapeutics 1Q 2026: Net loss $(18.9M), EPS $(0.35) — 10-Q Summary - TradingView
SAB Biotherapeutics (NASDAQ: SABS) posts larger Q1 2026 loss but boosts cash - Stock Titan
SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada
TradingKey - TradingKey
SABS Stock Price, Quote & Chart | SAB BIOTHERAPEUTICS INC (NASDAQ:SABS) - ChartMill
SABS shares surge 7.6% despite SAB Biotherapeutics deeper-than-expected quarterly loss; investors bullish on pipeline prospects.EBITDA Margin - newser.com
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET - Investing News Network
SAB Biotherapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
SAB BIO plans May 12 morning webcast on first-quarter results - Stock Titan
SAB Biotherapeutics and Emergent BioSolutions Sign Manufacturing and Supply Agreement for Drug Product Development - Minichart
EX-99.1 - SEC.gov
SAB Biotherapeutics Signs Manufacturing Pact for SAB-142 - TipRanks
SAB Biotherapeutics (SABS) sets 5-year, $36M post-approval SAB-142 manufacturing pact - Stock Titan
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Bioscience Association Manitoba
Millennium entities disclose 3.43M shares in SAB Biotherapeutics (SABS) - Stock Titan
SAB Biotherapeutics (SABS) Expected to Announce Earnings on Friday - MarketBeat
SAB Biotherapeutics (NASDAQ: SABS) outlines 2026 virtual annual meeting and board elections - Stock Titan
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 19.8% - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Shares Down 1.4%Here's What Happened - MarketBeat
SABS - Finviz
Emergent BioSolutions Signs $50 Million Contract to Support SAB Biotherapeutics' Lead Program - Moomoo
Sab Biotherapeutics Inc (SABS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Sab Biotherapeutics Inc 주식 (SABS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
0.98%
0.12%
자본화:
|
볼륨(24시간):